Page 551 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.5: Cost comparisons of watchful waiting with active treatments (continued)
Author Design Data Years N Methods Costs WW RP RT Notes
year source Population (95% (95% CI) (95% CI)
UI characteristics CI)
Wilson a236 Retrospective CaPSURE 1995-2004 WW = 238 Recurrent event Mean No statistical
2007 cohort study RP = 2496 analysis to cumulative comparison
17186528 BT = 668 calculate mean function cost was reported
EBRT = 409 cumulative over 5.5 yr for these
ADT = 607 functions of analyses.
Cryotherapy = prostate-related Total $ $ 32,795 $ 28,366
135 costs 31,871 [BT] (the authors
$ 48,840 claim to have
[We did not Medication $ 2832 [EBRT] “stratified” or
extract data on costs $ 5269 “controlled”
the costs of $ 3741 [BT] for patient
cryotherapy or $ 6515 age, risk
ADT] Office visit $ 18,116 [EBRT] group, and
costs $ ethnicity; it is
19,716 not clear if
$ 18,844 the extracted
Hospitalization $ 11,847 [BT] estimates
costs $ 36,446 were
$ 6886 [EBRT] adjusted for
these
[Low risk variables)
patients] $ 5780 [BT]
$ 5879
[EBRT]

a The study included an unknown number of T3a patients. Because such patients were considered “high risk”, we have only extracted information on the
subgroups of patients classified as “low” or “intermediate” risk.

C-193